544,153 Shares in Chimerix, Inc. (NASDAQ:CMRX) Bought by Trium Capital LLP

Trium Capital LLP acquired a new stake in shares of Chimerix, Inc. (NASDAQ:CMRX) in the 1st quarter, Holdings Channel reports. The firm acquired 544,153 shares of the biopharmaceutical company’s stock, valued at approximately $4,631,000. Chimerix accounts for about 0.6% of Trium Capital LLP’s holdings, making the stock its 12th biggest position.

Other institutional investors have also bought and sold shares of the company. Deerfield Management Company L.P. Series C purchased a new position in shares of Chimerix during the 4th quarter valued at approximately $13,124,000. Rosalind Advisors Inc. acquired a new position in shares of Chimerix during the 4th quarter valued at about $10,614,000. Millennium Management LLC boosted its position in shares of Chimerix by 6.8% during the 4th quarter. Millennium Management LLC now owns 2,557,530 shares of the biopharmaceutical company’s stock valued at $8,900,000 after acquiring an additional 161,795 shares during the last quarter. Marshall Wace LLP lifted its position in Chimerix by 1,318.5% in the fourth quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company’s stock valued at $7,705,000 after buying an additional 2,057,864 shares during the last quarter. Finally, Boxer Capital Management LLC acquired a new position in Chimerix in the fourth quarter valued at about $7,169,000. Institutional investors own 45.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen began coverage on shares of Chimerix in a research note on Sunday, May 18th. They set a “sell” rating on the stock.

Chimerix Price Performance

NASDAQ:CMRX opened at $8.54 on Wednesday. The company has a market capitalization of $801.09 million, a PE ratio of -9.09 and a beta of -0.17. Chimerix, Inc. has a 52-week low of $0.75 and a 52-week high of $8.55. The stock has a fifty day simple moving average of $8.54 and a 200-day simple moving average of $6.89.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.